Tissue analysis by artificial intelligence

Nucleai, a promising artificial intelligence (AI) start-up company in the pathology arena is making cancer diagnostics more accurate, accessible and efficient through AI-based analysis of biopsies.

Pathology is ripe for disruption, with a major shortage of pathologists coupled with an increasing demand for biopsies. Research shows that by 2030 the number of active pathologists may drop by 30% compared to 2010 levels.

Nucleai is addressing this by utilising decades of cumulative experience in AI and machine vision to work for and with pathologists, the only company to provide a comprehensive suite of solutions for cancer biopsies relating to gastrointestinal, breast and prostate analysis.

 

Other news

Upcoming Events

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Focus 2019

SEC Glasgow
1-3 May 2019

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Feb 2019

Early disease detection: a collaborative approach

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.